Navigation Links
UCI study points to new means of overcoming antiviral resistance in influenza
Date:7/12/2011

Irvine, Calif., July 12, 2011 UC Irvine researchers have found a new approach to the creation of customized therapies for virulent flu strains that resist current antiviral drugs.

Using powerful computer simulations, UCI's Rommie Amaro and Robin Bush created a method to predict how pocket structures on the surface of influenza proteins promoting viral replication can be identified as these proteins evolve, allowing for possible pharmaceutical exploitation.

"Our results can influence the development of new drugs taking advantage of this unique feature," said Amaro, assistant professor of pharmaceutical sciences and computer science. The study appears online in Nature Communications.

The search for effective flu drugs has always been hampered by the influenza virus itself, which mutates from strain to strain, making it difficult to target with a specific pharmaceutical approach.

The most common clinical flu treatments are broad-based and only partially effective. They work by interrupting the action of an enzyme protein in the virus called neuraminidase, which plays a critical role in viral replication.

In 2006, scientists discovered that avian influenza neuraminidase exhibited a distinctive, pocket-shaped feature in the area pinpointed by clinically used drugs. They named it the 150-cavity.

Amaro and Bush, associate professor of ecology & evolutionary biology, conducted research at the San Diego Supercomputer Center and the National Institute for Computational Sciences to learn the conditions under which the pockets form.

They created molecular simulations of flu proteins to predict how these dynamic structures move and change and where and when the 150-cavity pockets will appear on the protein surface. This sequence analysis method could be utilized on evolving flu strains, providing vital information for drug design, Amaro said.

She added: "Having additional antivirals in our treatment arsenal would be advantageous and potentially critical if a highly virulent strain for example, H5N1 evolved to undergo rapid transmission among humans or if the already highly transmissible H1N1 pandemic virus was to develop resistance to existing antiviral drugs."


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related biology news :

1. Owl study expands understanding of human stereovision
2. Virginia Tech Coal and Energy Center selected for study of CO2 injection into storage reservoirs
3. Large human study links phthalates, BPA and thyroid hormone levels
4. University of Houston researcher an author of multi-institutional genetic study of ovarian cancer
5. Study offers new clues about hereditary spastic paraplegia
6. Study suggests new strategy to prevent infertility, birth defects
7. UTMB-led researchers awarded $7.8 million for Gulf spill study
8. LSUHSC conducts landmark study of mid, long-term health effects of oil exposure
9. Nordic study shows marginally higher but overall low risk of stillbirth in ART children
10. First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference
11. Twin study shows lifestyle, diet can significantly influence course of macular degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... 2016 Elekta is pleased to ... its industry-leading treatment planning software, is available for clinical ... version 5.11 provides significant performance speed enhancements ... up to four times faster than in previous versions ... gold standard Monte Carlo algorithm, ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... screen mobile devices with fingerprint recognition for secure access, voice recognition for hands-free ... few ways consumers are interacting with biometrics technology today. But if they ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in ... pathogen detection. , PathSensors deploys the CANARY® test platform for the detection ...
Breaking Biology Technology: